-
Watch the Recording: Advocating for A Successful School Year
Recently, PPMD’s Alexis Hazlett was joined by panelists Jodi Krause (Colorado Children’s Hospital), Jill Castle, and Patrick Moeschen to discuss advocating for your child throughout the school year. The speakers dove into the differences between IEP (Individualized Educational Plan) and 504 plans, understanding your child’s educational rights, and shared tips to enhance communication and working…
-
Teaching students about life with limb-girdle muscular dystrophy
As most of America’s children go back to school, I thought it’d be timely to offer readers my perspective, as a retired teacher and wheelchair user, on the beginning of an academic year. I began teaching middle school music and band in the fall of 1995. I was 22 years old and had just graduated…
-
How my late brother and I left a mark on our DMD community
While observing World Duchenne Awareness Day over the weekend, I reflected on the journey my family and I have taken, which has been shaped by Duchenne muscular dystrophy (DMD). This year the Muscular Dystrophy Association (Singapore), or MDAS, celebrated the day during its annual Go the Dystance carnival. Growing up with DMD, I found that…
-
Lessons that come from a long journey with DMD
I walked home from school today. I’m almost 45 years old, yet today, with my backpack on, my empty lunch container stuffed inside, and a sweater tied around my waist, I walked home from school. As I pondered whether I was overthinking that image, my daughter Mary, 9, who goes to the same school where…
-
DYNE-251 leads to improvements in motor function in DMD: Update
Up to a year of treatment with DYNE-251, Dyne Therapeutics’ investigational exon 51-skipping therapy, led to improvements in motor function for boys with Duchenne muscular dystrophy (DMD), according to a clinical trial update. Based on these positive data from the Phase 1/2 DELIVER clinical trial (NCT05524883), Dyne is launching registrational groups of trial participants, the…
-
Raising Our Voices for Duchenne: Recap of PPMD’s Advocacy Webinar
On Thursday, September 5, 2024, PPMD hosted a special webinar, “PPMD Advocacy: Raising Our Voices in 2024 and Beyond,” bringing together advocates to reflect on PPMD’s advocacy efforts in our 30th anniversary year and discuss how we continue to drive policy change for those living with Duchenne and Becker muscular dystrophy. Moderated by PPMD’s Senior…
-
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
SEE THE FULL PRESS RELEASE BELOW AND HERE – Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne – – Announced in celebration of World Duchenne Awareness Day, grants are designed to fund efforts advancing diversity, equity, inclusion and accessibility within…
-
Myology Course Educates and Advances Next Generation of Neuromuscular Physicians and Scientists
PPMD is dedicated to fighting for every future as we strive to end Duchenne. Since 2011, PPMD has been a proud supporter of the Myology Course, presented by Nationwide Children’s Hospital (NCH) and The Ohio State University which aims to educate and advance the next generation of neuromuscular physicians and scientists. This commitment is essential…
-
CureDuchenne Submits Comments on FDA’s Draft Guidance for Industry on Platform Technology Designation Program
CureDuchenne welcomes the recent initiative the Food and Drug Administration (FDA) has taken to improve efficiencies in drug development, manufacturing, and the review process for new drug applications that incorporate designated platform technologies. This initiative is designed to help streamline the drug development and approval process, allowing drug companies to leverage prior knowledge from their…
-
Noninvasive qMRI seen to detect muscle changes in LGMD type R1
A noninvasive quantitative MRI, or qMRI, was found to detect early muscle abnormalities among people with limb-girdle muscular dystrophy type R1 (LGMDR1), according to a small study from Europe. Many of the qMRI findings correlated with clinical assessments of muscle function and patient-reported activities. “Our findings revealed alterations in both clinical outcome indicators and qMRI…
